Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 27;5(5):2260-2266.
doi: 10.1021/acsomega.9b03430. eCollection 2020 Feb 11.

Dibenzofuranylethylamines as 5-HT2A/2C Receptor Agonists

Affiliations

Dibenzofuranylethylamines as 5-HT2A/2C Receptor Agonists

Thirumal Yempala et al. ACS Omega. .

Abstract

The human 5-HT2 receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT2A and 5-HT2C subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We synthesized five phenethylamine analogs in which the benzene ring is replaced by a bulky dibenzo[b,d]furan moiety and found a couple with >70-fold 5-HT2C selectivity. Molecular docking studies of the most potent compound (5) at both receptor subtypes revealed the likely structural basis of its selectivity. Although in both cases, some crucial interactions are conserved, the change of the Ala2225.46 residue in the 5-HT2C receptor to the larger Ser2425.46 in the 5-HT2A subtype, which is the only structural difference between the orthosteric binding pockets of both receptors, weakens a π-π stacking interaction between the dibenzofuran moiety and the important Phe6.52 residue and breaks a hydrogen bond between the dibenzofuran oxygen and Ser5.43, explaining the selectivity of compound 5 for the 5-HT2C receptor. We believe that this effect of the residue at position 5.46 merits further exploration in the search for selective 5-HT2C receptor agonists that are of considerable interest in the treatment of schizophrenia and substance abuse.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structures of serotonin and 2,5-dioxygenated-4-substituted serotonin receptor ligands.
Figure 2
Figure 2
Structures of carbazole-derived beta blockers.
Figure 3
Figure 3
Dibenzofuranylethylamines synthesized and tested in this work.
Scheme 1
Scheme 1. DBF: Variously Substituted Dibenzo[b,d]furans
(a) AcOH/AcONH4+, reflux, 4 h, 84–88%. (b) THF, reflux, 16 h, then HCl/acetone, 65–72%.
Figure 4
Figure 4
Overlaid crystal structure of the 5-HT2C receptor (cyan) and model of the 5-HT2A receptor (yellow-tan). The bound ergoline in the crystal is shown in magenta. Nonconserved residues are shown as sticks.
Figure 5
Figure 5
Key interactions of 5 in the orthosteric binding site of 5-HT2C and 5-HT2A receptors (colored slate blue). Nonconserved residues in 5-HT2C/2A receptors at position 5.46 (yellow for A2225.46 in 5-HT2C (A) and cyan for S2425.46 (B) in 5-HT2A, respectively). According to our docking results, this difference results in a significant weakening of the π–π interaction with F6.52 and of the hydrogen bond between the dibenzofuranyl oxygen atom and S5.43.
Figure 6
Figure 6
Comparison of the structures of compound 3, 2C-phenyl, and “Fly” (with dihydrofuran rings) and “Dragonfly” compounds (with furan rings).

References

    1. Chagraoui A.; Thibaut F.; Skiba M.; Thuillez C.; Bourin M. 5-HT2C receptors in psychiatric disorders: A review. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2016, 66, 120–135. 10.1016/j.pnpbp.2015.12.006. - DOI - PubMed
    1. Palacios J. M.; Pazos A.; Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology 2017, 234, 1395–1418. 10.1007/s00213-017-4545-5. - DOI - PubMed
    1. Pogorelov V. M.; Rodriguiz R. M.; Cheng J.; Huang M.; Schmerberg C. M.; Meltzer H. Y.; Roth B. L.; Kozikowski A. P.; Wetsel W. C. 5-HT2C agonists modulate schizophrenia-like behaviors in mice. Neuropsychopharmacology 2017, 42, 2163–2177. 10.1038/npp.2017.52. - DOI - PMC - PubMed
    1. Huang X.-P.; Setola V.; Yadav P. N.; Allen J. A.; Rogan S. C.; Hanson B. J.; Revankar C.; Robers M.; Doucette C.; Roth B. L. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2Breceptor agonists: Implications for drug safety assessment. Mol. Pharmacol. 2009, 76, 710–722. 10.1124/mol.109.058057. - DOI - PMC - PubMed
    1. Shulgin A. T.; Shulgin A.. PIHKAL, Phenethylamines I Have Known and Loved, Transform Press, Berkeley, CA. 1991.

LinkOut - more resources